Search results for "Protocol"

showing 10 items of 1808 documents

How to demonstrate that eSET does not compromise the likelihood of having a baby?

2009

BACKGROUND: In several randomized studies, elective single embryo transfer (eSET) has proven its effectiveness in reducing twin pregnancy rates while obtaining acceptable overall pregnancy rates. However, there is no outcome measurement consensus to evaluate the effectiveness of eSET versus double-embryo transfer (DET). METHODS: This study evaluated whether or not adopting an eSET strategy instead of a DET strategy lowers the probability of having at least one live-born infant in good prognosis couples. Seven hundred and twenty-six couples were divided into two groups. The retrospective arm of the study was undertaken on the first group of couples (n = 483, DET group) and the prospective ar…

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentStatistics as TopicSingle Embryo TransferMultiple Birth OffspringIntracytoplasmic sperm injectionClinical ProtocolsPregnancyOutcome Assessment Health CaremedicineSingle Embryo TransferHumansPregnancyObstetricsbusiness.industryRehabilitationObstetrics and Gynecologymedicine.diseaseEmbryo TransferOutcome (probability)Embryo transferPregnancy rateReproductive MedicineInfertilityObservational studyFemalebusinessLive birthHuman reproduction (Oxford, England)
researchProduct

Efficacy and acceptability of pharmacological and non-pharmacological interventions for non-specific chronic low back pain: a protocol for a systemat…

2020

Abstract Background Despite the enormous financial and humanistic burden of chronic low back pain (CLBP), there is little consensus on what constitutes the best treatment options from a multitude of competing interventions. The objective of this network meta-analysis (NMA) is to determine the relative efficacy and acceptability of primary care treatments for non-specific CLBP, with the overarching aim of providing a comprehensive evidence base for informing treatment decisions. Methods We will perform a systematic search to identify randomised controlled trials of interventions endorsed in primary care guidelines for the treatment of non-specific CLBP in adults. Information sources searched…

Adultmedicine.medical_specialtyPsychological interventionMEDLINEMedicine (miscellaneous)lcsh:Medicinenot knownlaw.inventionRS03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled trialMeta-Analysis as TopiclawmedicineProtocolHumansLow back pain030212 general & internal medicineFunctional abilityNetwork meta-analysisExercisebusiness.industrylcsh:RBayes TheoremLow back painClinical trialRandomized controlled trialMeta-analysisPhysical therapySystematic reviewQuality of Lifemedicine.symptombusiness030217 neurology & neurosurgerySystematic Reviews as TopicSystematic Reviews
researchProduct

Progestogens to prevent preterm birth in twin pregnancies:an individual participant data meta-analysis of randomized trials

2012

Abstract Background Preterm birth is the principal factor contributing to adverse outcomes in multiple pregnancies. Randomized controlled trials of progestogens to prevent preterm birth in twin pregnancies have shown no clear benefits. However, individual studies have not had sufficient power to evaluate potential benefits in women at particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to determine adverse effects for rare outcomes such as intrauterine death. Methods/design We propose an individual participant data meta-analysis of high quality randomized, double-blind, placebo-controlled trials of progestogen treatment in women with …

Adultmedicine.medical_specialtyReproductive medicine/dk/atira/pure/subjectarea/asjc/2700/2729lcsh:Gynecology and obstetricslaw.inventionStudy ProtocolClinical ProtocolsRandomized controlled trialPregnancylawObstetrics and GynaecologymedicineHumansAdverse effectTwin Pregnancylcsh:RG1-991Randomized Controlled Trials as TopicPregnancyModels StatisticalObstetricsbusiness.industryIndividual participant dataInfant NewbornPregnancy OutcomeObstetrics and Gynecologymedicine.diseasePregnancy ComplicationsPremature birthMeta-analysisPregnancy TwinPremature BirthFemaleProgestinsbusiness
researchProduct

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

2007

Abstract Background The objective of this study is to evaluate the efficacy and toxicity of the liposome-encapsulated doxorubicin (TLC D-99) plus cyclophosphamide (CTX) as first-line treatment of metastatic breast cancer in light of the potential cardioprotective effect of TLC D-99 as compared with conventional doxorubicin. Materials and methods Sixty-seven patients as defined according Simon's two-stage phase II design were enrolled. They received TLC D-99 at the dosage of 60 mg/m2 plus CTX 600 mg/m2, with cycles repeated every 3 weeks. Cardiac function was assessed by ultrasonography at baseline and every two cycles. Results The principal characteristics of the 67 enrolled patients were a…

Adultmedicine.medical_specialtySkin NeoplasmsCyclophosphamideSettore MED/06 - Oncologia MedicaPhases of clinical researchBreast NeoplasmsSoft Tissue NeoplasmsAsymptomaticGastroenterologyDrug Delivery SystemsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAntineoplastic Agents AlkylatingCyclophosphamideAgedAntibiotics AntineoplasticPerformance statusbusiness.industryHematologyMiddle Agedmedicine.diseasedoxorubicin cyclophosphamide breast cancerMetastatic breast cancerSurgeryOncologyDoxorubicinLiposomesToxicityCarcinoma Squamous CellFemalemedicine.symptombusinessmedicine.drug
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.

1985

Modulation of steroid status by conventional chemotherapy was studied in 31 breast cancer patients receiving CMF and in 31 age-matched breast cancer patients without any therapy, taken as controls. This was achieved through the study of oestrogen excretion profiles using previously identified parameters and referring not only to classical but also to the “other”, namely catechol and unusual, oestrogen metabolites. After CMF treatment the premenopausal patients exhibit a modified excretion pattern, mainly concerning a marked and significant reduction of classical oestrogens, as shown by pattern indices. Because there is evidence that oestriol metabolism is not markedly affected by CMF treatm…

Adultmedicine.medical_specialtyTime FactorschlormethineAdjuvant chemotherapymedicine.medical_treatmentBreast NeoplasmsBiochemistryestriolGas Chromatography-Mass SpectrometrySteroidExcretionEndocrinologyBreast cancerInternal medicineestradiolAntineoplastic Combined Chemotherapy ProtocolsmedicineestrogenHumansStage (cooking)CyclophosphamideChromatography High Pressure LiquidAgedbusiness.industryEstrogensMetabolismMiddle Agedmedicine.diseaseestroneEstrogens CatecholEndocrinologyMethotrexateMetabolic rateAdrenal CortexFemaleFluorouracilMenopausebusinessAfter treatmentJournal of steroid biochemistry
researchProduct

Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.

2001

Summary Purpose To date the systemic treatment of recurrent and/or metastatic adenocarcinoma of the endometrium (EAC), using both chemotherapy and hormonotherapy (HT), is far from satisfactory. The significant activity of vinorelbine (VNR), a relatively new semisynthetic vinca alkaloid, demonstrated in advanced breast cancer, bronchial adenocarcinoma, and in head and neck cancer, prompted us to carry out a phase II trial employing the combination of cisplatin and VNR in a pluri-institutional series of patients with recurrent and/or metastatic EAC. Patients and methods Thirty-five patients affected by recurrent and/or metastatic EAC have been treated with CDDP 80 mg/m2 on day 1 plus VNR 25 m…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentAdministration OralAdenocarcinomaVinorelbineVinblastineGastroenterologyVinca alkaloidBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAgedChemotherapybusiness.industryVinorelbineHematologyMiddle AgedMetastatic Endometrial Adenocarcinomamedicine.diseaseChemotherapy regimenSurgeryEndometrial NeoplasmsSurvival RateRegimenOncologyAdenocarcinomaFemaleCisplatinbusinessmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: An Italian clinical experience

2011

Aims and Background: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone- refractory prostate cancer (mHRPC). Methods: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints. Results: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients…

Aged 80 and overMaleTime FactorsAntineoplastic Agents HormonalSettore MED/06 - Oncologia MedicaProstatic NeoplasmsDocetaxelAdenocarcinomaMiddle AgedProstate-Specific AntigenTreatment OutcomeItalyDrug Resistance NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionHumansPrednisoneTaxoidsAdenocarcinoma Antineoplastic combined chemiotherapy protocols Docetaxel Drug-resistace Neoplasm Prednisone Prostatic neoplasm TaxoidsAgedNeoplasm Staging
researchProduct

The design of an agent based model of human activities and communications in cardiac resuscitation

2015

International audience; Cardio-pulmonary arrest is a common emergency situation causing over 400,000 deaths per year, more than a 1000 per day, in the USA alone. The goal of this work is to develop an agent based computer simulator that will allow trainers to experiment with different communication protocols, such as those found in air traffic control. This paper describes the first step in designing the simulator development. The design is based on an analysis of communications during real life training simulations using the FIPA standard categories.

Agent-based modelFOS: Computer and information sciencesComputer sciencebusiness.industryAir traffic controlAdvanced life supportCardiac resuscitationComputer Science - Computers and SocietyHandover[INFO.INFO-MA]Computer Science [cs]/Multiagent Systems [cs.MA]Computers and Society (cs.CY)Computer Science - Multiagent SystemsSoftware engineeringbusinessCommunications protocolSimulationMultiagent Systems (cs.MA)
researchProduct